BALYASNY ASSET MANAGEMENT L.P. - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 230 filers reported holding NEKTAR THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.0%.

Quarter-by-quarter ownership
BALYASNY ASSET MANAGEMENT L.P. ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q3 2023$794,333
+3005.4%
1,333,668
+2899.0%
0.00%
Q2 2023$25,579
-44.4%
44,470
+206.4%
0.00%
Q3 2022$46,000
-98.7%
14,512
-97.8%
0.00%
-100.0%
Q1 2022$3,605,000
+775.0%
668,827
+2094.3%
0.01%
+1000.0%
Q4 2021$412,000
-86.8%
30,480
-82.4%
0.00%
-92.3%
Q3 2021$3,116,000
+7.5%
173,518
+29.2%
0.01%
-23.5%
Q4 2019$2,898,000
-49.7%
134,277
-17.0%
0.02%
-54.1%
Q2 2019$5,758,000
-1.2%
161,829
-6.7%
0.04%
-5.1%
Q1 2019$5,827,000
+77.7%
173,431
+73.8%
0.04%
+62.5%
Q4 2018$3,280,000
-71.7%
99,794
-51.0%
0.02%
-54.7%
Q3 2018$11,594,000
+177.6%
203,501
+417.8%
0.05%
+211.8%
Q1 2018$4,176,000
-69.5%
39,300
-82.8%
0.02%
-59.5%
Q4 2017$13,676,000
-28.1%
229,000
-71.1%
0.04%
-44.0%
Q3 2017$19,027,000
+90.5%
792,782
+55.1%
0.08%
+82.9%
Q2 2017$9,990,000
-2.8%
511,013
+16.7%
0.04%
-14.6%
Q1 2017$10,276,000
+1955.2%
437,822
+1376.9%
0.05%
+1500.0%
Q4 2015$500,000
+148.8%
29,645
+84.5%
0.00%
+200.0%
Q2 2015$201,00016,0650.00%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q2 2022
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 1,828,400$89,281,0006.61%
Cormorant Asset Management, LP 1,500,000$73,245,0005.42%
Camber Capital Management LP 2,000,000$97,660,0003.76%
Rhenman & Partners Asset Management AB 617,652$30,160,0003.09%
BRIDGER MANAGEMENT, LLC 1,134,414$55,393,0003.00%
First Light Asset Management, LLC 374,251$18,275,0002.84%
Gs Investments, Inc. 54,000$2,636,820,0001.97%
SABBY MANAGEMENT, LLC 241,922$11,813,0001.82%
QUANTRES ASSET MANAGEMENT Ltd 50,000$2,441,0001.41%
Tibra Equities Europe Ltd 173,183$8,457,0001.27%
View complete list of NEKTAR THERAPEUTICS shareholders